Takeda has high hopes for its new chief; AB Science loses out on EMA nod;

@FierceBiotech: European regulators hand Novartis a big setback on a top blockbuster prospect. Coverage | Follow @FierceBiotech

@JohnCFierce: All PTC Therapeutics has ever done with ataluren is fail and fail again. Now its stock is down 20% on a completely predictable action by the EMA. More | Follow @JohnCFierce

@DamianFierce: GlaxoSmithKline clears an EU hurdle with its once-delayed GLP-1 diabetes drug. More | Follow @DamianFierce

@EmilyMFierce: Genetic platform developed by University of California, San Diego researchers screens marine microbiota for new compounds. Story from FierceBiotech Research | Follow @EmilyMFierce

> Takeda is counting on incoming CEO Christophe Weber to lead the charge for innovation at the Japanese drugmaker, and the soon-to-step-down Yasuchika Hasegawa told Reuters he expects his replacement to come up with some new ideas "within three to six months." Story

> AB Science failed to win a recommendation from a European Medicines Agency advisory committee for Masiviera, its long-suffering treatment for pancreatic cancer. Article

Medical Device News

@FierceMedDev: Revenue ticks up as Covidien braces for transition. Story | Follow @FierceMedDev

@MichaelGFierce: Intuitive Surgical released 4th quarter earnings. Report (PDF) | Follow @MichaelGFierce

@EmilyWFierce: Neurons "talk to each other," spread epileptic activity in the brain according to researchers. Release | Follow @EmilyWFierce

@GalenMoore: Grim: FDA warned the VA about these human tissue suppliers. VA kept using them anyway. Story via Bloomberg | Follow @GalenMoore

> FDA grants humanitarian use for Miltenyi's stem cell transplant device. News

> Itamar connects with a U.S. nutrition firm to market its home sleep apnea Dx. More

Pharma News

@FiercePharma: New York plant that makes Diovan is next on Novartis' shutdown list. Story | Follow @FiercePharma

@TracyStaton: Q4 sales up, 2013 down, esp in US: Bristol-Myers Squibb Reports 4th Quarter and Full Year 2013 Results. Release | Follow @TracyStaton

@EricPFierce: Par's decision to buy JHP for $490M will inject new competition into sterile drug manufacturing. Story | Follow @EricPFierce

@CarlyHFierce: Under investor pressure, Teva chairman pledges smaller, more experienced board. Story | Follow @CarlyHFierce

> Ranbaxy falls further into regulatory quagmire with latest FDA ban. Story

> EMA hands Novartis good news on Xolair but a rebuke for serelaxin. Report

> EMA reviews emergency contraceptives for their effectiveness in heavier women. More

Suggested Articles

Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.

The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.

Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.